Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2037 - Multidimensional telemonitoring of cancer patients (pts) receiving chronomodulated (chrono) Irinotecan (I), 5-Fluorouracil (F), Leucovorin (L) and Oxaliplatin (O; chronoIFLO4) combination at home


10 Sep 2017


Poster display session


Cytotoxic Therapy;  Psychosocial Aspects of Cancer;  Supportive and Palliative Care


Pasquale Innominato


Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388


P. Innominato1, S. Komarzynski1, M. Bouchahda2, A. Ulusakarya3, M. Haydar2, A. Karaboué4, F. Levi1

Author affiliations

  • 1 Medical School, University of Warwick, CV4 7AL - Coventry/GB
  • 2 Oncology, Paul Brousse Hospital, Villejuif/FR
  • 3 U935, INSERM, Villejuif/FR
  • 4 Research & Therapeutic Innovation, AK-SCIENCE, Vitry-sur-Seine/FR


Abstract 2037


FOLFIRINOX is an active yet toxic regimen against intestinal cancers. Improving its tolerability could widen its use in routine clinical practice. Circadian-based chrono administration of this triplet can be performed using a multichannel programmable-in-time pump. Here, we show the safety of chronoIFLO4 at home, through real-time multidimensional telemonitoring of circadian rest-activity rhythm (CircAct), sleep, patient-reported outcome measures (PROM) and body weight changes (BWC) using 1st generation e-Health platform inCASA.


Pts received Day (D)1 chrono I (180 mg/m2, over 6-h; peak rate at 5:00), and D 2-4 chrono O (25 mg/m2/d, over 11.5-h; peak rate at 16:00) and F-L (800 mg/m2/d and 400 mg/m2/d, respectively, over 11.5-h; peak rate at 04:00), q2 weeks at home. Pts completed the 19-item MD Anderson Symptom Inventory (MDASI) on an interactive electronic screen, weighed themselves on a dedicated scale, and continuously wore a watch-sized wrist-accelerometer for CircAct and sleep monitoring. Daily data were securely teletransmitted via Internet to a specific server accessible by the hospital team. The validated and clinically-relevant CircAct parameter I


Eleven patients (48-72 years; 45% males; 27% PS = 0) received 26 cycles (cy) of chronoIFLO4, and provided 5,891 data points/8,736 expected (67.4%). No grade 3-4 clinical toxicity occurred. The most severe MDASI scores remained low: interference with work (mean: 5.1/10) or general activity (4.9); fatigue (4.9); distress (4.2) and appetite loss (3.6). Mean BWC was -0.9% and mean SE remained above 82%. CircAct disruption (I


ChronoIFLO4 represents a safe therapeutic option at home, and the pt-centered multidimentional telemonitoring solution allows the design of innovative management approaches, ultimately improving pt experience with chemotherapy, safety and outcomes.

Clinical trial identification

Legal entity responsible for the study

INSERM and European Commission




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.